Navigation Links
Most men with low-risk prostate cancer receive aggressive treatment
Date:7/26/2010

Most men who are diagnosed with prostate cancer appear to under undergo aggressive therapy, even if they have a low prostate-specific antigen (PSA) level and low-risk disease, according to a report in the July 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

More than 90 percent of all prostate cancers are diagnosed before the disease has spread to other parts of the body, and the five-year survival rate for these patients diagnosed with localized disease is almost 100 percent, according to background information in the article. The five-year survival rate from all stages of disease increased from 69 percent in 1975 to almost 99 percent in 2003. "The tremendous improvement in survival has been attributed to early detection and treatment," the authors write. "However, there have been concerns about the potential overdiagnosis and overtreatment of localized prostate cancer. Despite these concerns, some researchers argue that the prostate-specific antigen (PSA) level is associated with a continuum of cancer risk and recommend lowering the 4-nanogram per milliliter threshold for biopsy."

To determine current risk profiles and treatment patterns of men with prostate cancer and PSA levels below this threshold, Yu-Hsuan Shao, Ph.D., of the Cancer Institute of New Jersey, New Brunswick, and colleagues used data from the Surveillance, Epidemiology and End Results system. Of 123,934 men with newly diagnosed prostate cancer from 2004 to 2006, 14 percent had PSA levels of 4 nanograms per milliliter or lower. "The patients in these cases were less likely to have high-grade cancer, and more than half were classified as having low-risk cancer," the authors write.

"Despite their lower risk of having clinically significant disease, treatment rates for men with PSA values of 4.0 nanograms per milliliter or lower were comparable to those of men presenting with PSA values between 4.0 and 20.0 nanograms per milliliter." More than 70 percent of men with PSA values lower than 20 nanograms per milliliter had their prostates removed via radical prostatectomy or had radiation therapy. "Radical prostatectomy was performed on 44 percent of men with PSA values of 4.0 nanograms per milliliter or lower, 38 percent of men with PSA values between 4.1 and 10.0 nanograms per milliliter and 24 percent of men with PSA values between 10.1 and 20 nanograms per milliliter. Radiation therapy was performed on 33 percent of men with PSA values of 4.0 nanograms per milliliter or lower, 40 percent of men with PSA values between 4.1 and 10.0 nanograms per milliliter and 41.3 percent of men with PSA values between 10.1 and 20 nanograms per milliliter," the authors write.

The authors suggest that if the threshold PSA value for biopsy were decreased from 4.0 to 2.5 nanograms per milliliter, the number of men with abnormal PSA levels would double to approximately 6 million. "Estimates suggest that 32 percent of men with abnormal PSA levels would be diagnosed as having prostate cancer from their needle biopsy," they write. "Based on the results in the present study, 82.5 percent of these 1.9 million men would receive attempted curative treatments, while only 2.4 percent would have high-grade cancer. However, no evidence suggests that delaying biopsy until the PSA level reaches 4.0 nanograms per milliliter would result in an excessive number of potentially non-curable disease cases."

"These results underscore the fact that PSA level, the current biomarker, is not a sufficient basis for treatment decisions," the authors conclude. "Without the ability to distinguish indolent from aggressive cancers, lowering the biopsy threshold might increase the risk of overdiagnosis and overtreatment."


'/>"/>

Contact: Michele Fisher
fisherm2@umdnj.edu
732-235-9872
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. What is the role of focal therapy in low-risk prostate cancer?
2. Value of Monitoring Low-Risk Prostate Cancer Assessed
3. Delay in surgery not likely to worsen tumors in men with low-risk prostate cancer
4. Surveillance may be suitable treatment option for patients with low-risk prostate cancer
5. Advance Toward Test for Aggressive Prostate Cancer
6. DASH FOR DAD Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
7. Jim Huber to Serve as National Spokesman for Know Your Score: Fight Prostate Campaign at Myrtle Beach Golf Holiday in August
8. Few differences in outcomes between open and laparoscopic prostate surgery
9. Two Surgical Methods Equally Successful for Prostate Cancer
10. Genetic Mutation Linked to Prostate Cancer in Blacks
11. Statins May Benefit Prostate Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... 18, 2017 , ... Inc. magazine has ranked American Specialty Health, Incorporated (ASH) ... nation's fastest-growing private companies. This marks the eighth time in the last nine years ... year’s ranking reflects ASH’s 76 percent overall revenue growth from 2013 ($239 million) through ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Three Narrow Roads”: a vivid ... creation of published author, Rev. Dr. Burnett King Sr., is currently the pastor-teacher-visionary at ... of the Faith Track Club, Inc., a track-and-field program geared towards youth. , King ...
(Date:8/18/2017)... ... ... “Kingdom Mandate for Kingdom Builders”: a call to walk as citizens of the ... creation of published author, John F. McGeorge, Jr. Dr. John F. McGeorge Jr., ... He spent three decades training pastors and Christian leaders. He also met his ...
(Date:8/17/2017)... Goldsboro, NC (PRWEB) , ... August 17, 2017 ... ... multi-specialty dental practice, is adding a new location in Goldsboro, NC to its ... trusted care that is Riccobene Associates’ trademark starting August 15, 2017. , ...
(Date:8/17/2017)... ... 17, 2017 , ... Industry CEOs, life science leaders, influential ... This off-the-record networking forum of the Boston Biotech Conference series will be held ... leaders and decision makers will discuss issues facing the development of anti-infective, antiviral, ...
Breaking Medicine News(10 mins):
(Date:8/18/2017)... , Aug. 18, 2017  Nortis today announced the ... funding for the third year of a Small Business ... National Institute of Neurological Disorders and Stroke (NINDS).?  ... Nortis ParVivo ... ...
(Date:8/17/2017)... 2017 MJAC2017 , the premier cannabis event ... today reveals its leading lineup. MJAC2017 ... cannabis innovator specializing in the development of pharmaceutical and consumer ... Rambridge™ and The Green Organic Dutchman are gold sponsors for ... silver sponsors. ...
(Date:8/17/2017)... DarioHealth Corp. (NASDAQ: DRIO), a leading ... big data solutions, announced today that it has ... investors for the sale of shares of the ... newly designated Series B Convertible Preferred Stock in ... conduct a closing with respect to the offerings ...
Breaking Medicine Technology: